| Prev Close | 10.16 |
| Open | 10.17 |
| Day Low/High | 10.10 / 10.64 |
| 52 Wk Low/High | 9.71 / 73.03 |
| Volume | 129.53K |
Editas Medicine, Inc. (EDIT)
10.79
0.63
6.20
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 68.64B |
| Market Cap | 685.71M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Premarket Movers
Upside - +90% (FDA grants Regenerative Medicine Advanced Therapy designation to SkinTE) - +37% (earnings, guidance) - +23% (Emergent Fidelity Technologies discloses 7.6% stake; crypto stocks higher as token prices and Tether stabilize) - +20% (earni...
Jim Cramer: Monday's Market Is One of the Most Mind-Blowing I've Seen
Buyers make or break companies with their voting or buying or betting. Somedays it's all that matters.
Are You Investing -- Or Just Gambling?
Here's the difference between the two, using two biotech companies, Mannkind and Editas.
4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech
These ARK Funds family funds are focused on new opportunities and investment themes.
Netflix and Twitter Are Among 29 Stocks Ready to Change Direction
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
3 Potential Biotech Buyout Targets in the Second Quarter
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Possible Biotech Takeout Plays
A look at possible second-quarter M&A activity in the biotech sector.
Buy Opportunities Dry Up as Stock Market 'Gaps and Slips'
You have to be willing to chase if you want to establish new positions.
Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers
The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.
Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers
The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.
KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers
Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.
M&A Could Ignite Next Leg Up for Biotech
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
